The case of transthyretin familial amyloid polyneuropathy: diagnostic search
- Authors: Smirnov A.P1, Serdyuk A.V1, Kovrazhkina E.A1
-
Affiliations:
- N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 20, No 9 (2018)
- Pages: 58-62
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95090
- DOI: https://doi.org/10.26442/2075-1753_2018.9.58-62
- ID: 95090
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A. P Smirnov
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. неврологии, нейрохирургии и медицинской генетики 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
A. V Serdyuk
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federationканд. мед. наук, ассистент каф. неврологии, нейрохирургии и медицинской генетики 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
E. A Kovrazhkina
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: elekov2@yandex.ru
канд. мед. наук, ст. науч. сотр. НИИ цереброваскулярной патологии и инсульта 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
References
- Зиновьева О.Е., Сафиулина Э.И. Транстиретиновая амилоидная полинейропатия: патогенез, клинические особенности, перспективы лечения. Manage pain. 2017; 4: 12-5.
- Benson M.D, Kincaid J.C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36: 411-23.
- Sekiijima Y, Kelly J.W, Ikeda S. Pathogenesis of therapeutic strategies of ameliorate the transthyretin amyloidoses. Curr Pharm des 2008; 14 (30): 3219-30.
- Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86 (9): 1036-43.
- Barreiros A.P, Galle P.R, Otto G. Familial amyloid polyneuropathy. Diq Dis 2013; 31 (1): 170-4.
- Saraiva M.J.M, Costa P.P, Goodman D.S. Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type. Trans Res 1983; 102 (4): 590-603.
- Plantе-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurology 2011; 10 (12): 1086-97.
- Cruz M.W, Schmidt H, Botteman M.F et al. Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases. Amyloid 2017; 24 (1): 109-10.
- Hou X, Aguilar M.I, Small D.H. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007; 274 (7): 1637-50.
- Falk R.H, Comenzo R.L, Skinner M. The systemic amyloidoses. N Eng J Med 1997; 337: 898-909.
- Plante-Bordeneuve V, Ferreira A, Lalu T et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007; 69: 693-8.
- Adams D, Suhr O.B, Hund E et al, European Network for T.-F. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016; 29 (Suppl. 1): S14-26.
- Schmidt H, Cruz M.W, Botteman M.F et al. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. Amyloid 2017; 24 (1): 111-2.
- Ando Y, Nakamura M, Araki S. Transthyretin-related familiar amyloidic polyneuropathy. Arch Neurol 2005; 62: 1057-62.
- Ando Y, Coelho T, Berk J.L et al. Guideline of transthyretin-related hereditary amyloidodid for clinicals. Orphanet J Rare Dis 2013; 8: 31.
- Ueda M, Ando Y. Recent anvances in transthyretin amylodosis therapy. Transl Neurodegener 2014; 3: 19.
- Benson M.D et al. Transthyretin amyloidosis. Amyloid 1996; 3: 44-56.
- Ikeda S, Yanagisawa N, Hongo M, Ito N. Vagus nerve and celiac ganglion lesions in generalized amyloidosis: a correlative study of familial amyloid polyneuropathy and AL-amyloidosis. J Neurol Sci 1987; 79 (1): 129-39.
- Зиновьева О.Е., Умари Д., Солоха О., Яхно Н. Амилоидная невропатия у пациента с транстиретиновым семейным амилоидозом. Неврол. журн. 2016; 5: 305-12.
- Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 2013; 119: 129-39.
- Nakamura M, Yamashita T, Ueda M et al. Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis. Neurology 2005; 65 (7): 1051-6.
- Algarrondo V, Dinanian S, Juin C et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm 2012; 9: 1069-75.
- Rousseau A, Kaswin G, Adams D et al. Ocular involvement in familial amyloid polyneuropathy. J Fr Ophtalmol 2013; 36: 779-88.
- Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012; 7: 1337-46.
- Sousa A, Andersson R, Drugge U et al. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Human heredity 1993; 43 (5): 288-94.
- Adams D, Lorezon P, Lacroix C. Amyloid neuroparthies. Curr Opin Neurol 2012; 25: 564-72.
- Adams D, Loreson P, Theaudin M et al., French Network for FAP. Regional difference and similarity of familial amyloid polyneuropathy in France. Amyloid 2012; 19: 61-4.
- Do A.B, Coelho T, Sousa A, Guimaraes A. Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguesse type. Amyloid 2009; 16: 232-8.
- Westermark P. Subcutaneous adipose tissue biopsy for amyloid protein studies. Methods Mol Biol 2012; 849: 363-71.
- Kyle R.A, Spencer R.J, Dahlin D.C. Value of rectal biopsy in the diagnosis of primary systemic amyloidosis. Am J Med Sci 1966; 251: 501-6.
- Picken M.M, Westermark P. Amyloid detection and typing: summary of current practice and recommendations of the consensus group. Amyloid 2011; 18: 48-50.
- Merlini G, Westermark P. The systemic amyloidoses clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 69: 159-78.
- Holmgren G, Ericzon B.G, Groth C.G et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidisis. Lancet 1993; 341: 1113-6.
- Ericzon B.G, Wilczek H.E, Larsson M et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 2015; 99: 1847-54.
- Liepnieks J.J, Benson M.D. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantaton. Amyloid 2007; 14: 277-82.
- Rapezzi C, Perugini E, Salvi F et al. Phenotypic and genotypic heterogeneity in transthyrerin-related cardiac amyloidisis: towards tailoring of therapeutic strategies? Amyloid 2006; 13: 143-53.
- Coelho T, Maia L.F, Martins da S.A et al. Tadamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785-92.
- Berk J.L, Suhr O.B, Obici L et al., Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658-67.